- Home
- BHFAN vs MIRM Comparison
BHFAN vs MIRM Comparison
Compare BHFAN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BHFAN
- MIRM
- Stock Information
- Founded
- BHFAN N/A
- MIRM 2018
- Country
- BHFAN United States
- MIRM United States
- Employees
- BHFAN 1400
- MIRM N/A
- Industry
- BHFAN Life Insurance
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- BHFAN Finance
- MIRM Health Care
- Exchange
- BHFAN Nasdaq
- MIRM Nasdaq
- Market Cap
- BHFAN N/A
- MIRM 1.9B
- IPO Year
- BHFAN N/A
- MIRM 2019
- Fundamental
- Price
- BHFAN $15.76
- MIRM $40.00
- Analyst Decision
- BHFAN
- MIRM Strong Buy
- Analyst Count
- BHFAN 0
- MIRM 11
- Target Price
- BHFAN N/A
- MIRM $58.55
- AVG Volume (30 Days)
- BHFAN N/A
- MIRM 447.2K
- Earning Date
- BHFAN N/A
- MIRM 05-07-2025
- Dividend Yield
- BHFAN N/A
- MIRM N/A
- EPS Growth
- BHFAN N/A
- MIRM N/A
- EPS
- BHFAN N/A
- MIRM N/A
- Revenue
- BHFAN N/A
- MIRM $336,888,000.00
- Revenue This Year
- BHFAN N/A
- MIRM $29.51
- Revenue Next Year
- BHFAN N/A
- MIRM $20.27
- P/E Ratio
- BHFAN N/A
- MIRM N/A
- Revenue Growth
- BHFAN N/A
- MIRM 80.76
- 52 Week Low
- BHFAN N/A
- MIRM $23.14
- 52 Week High
- BHFAN N/A
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- BHFAN 51.02
- MIRM 41.05
- Support Level
- BHFAN $15.01
- MIRM $38.22
- Resistance Level
- BHFAN $15.45
- MIRM $40.14
- Average True Range (ATR)
- BHFAN 0.47
- MIRM 2.24
- MACD
- BHFAN 0.08
- MIRM 0.07
- Stochastic Oscillator
- BHFAN 92.42
- MIRM 48.50
About BHFAN Brighthouse Financial Inc. Depositary shares each representing a 1/1000th interest in a share of 5.375% Non-Cumulative Preferred Stock Series C
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.